GeneMedi SOLIDEX™ Cell Therapy Solutions

ISOEx Immunocytes Cell Isolation Immunomagnetic Beads

Function: High-purity enrichment of specific immune cells or stem cells for downstream experiments.

Product Highlights:

• Optimized antibodies targeting CD3, CD4, CD8, CD14, CD19, CD34, NK (CD56), monocytes (CD14), and more.

Core Technologies:

Category	Type	Description	Advantages	Disadvantages
Labeling Method	Direct cell isolation	Antibodies directly conjugated to magnetic beads	Fastest method (single-step) High specificity Simple protocol	Limited flexibility High capacity to antibodies
	Indirect cell isolation	Uses biotinylated secondary capture (reusable beads)	Antibody flexibility Cost-effective Signal amplification possible	Longer protocol Potential for higher background Additional step required
Bead Type	Releasable	Allow competitive elution	Better for sensitive applications Simple workflow	More expensive beads May interfere with some tasks
	Non-releasable	Form irreversible bonds (Streptavidin beads)	Ideal for negative selection More economical	Permanent bead attachment
Format	Column-based	Uses magnetic columns with 50nm beads	Highest purity	Requires columns Slower processing Higher cost
	Column-free	Uses larger beads with external magnets	Fast processing (<15 min) No column costs	Slightly lower purity Less suitable for automation

Detail

CDEx Flow Cytometry Antibodies

Function: Multiplexed, high-sensitivity analysis of immune cell phenotypes at the single-cell level.

Product Portfolio:

• PE/APC/FITC-Conjugated Antibodies: Targeting CD3E, CD4, CD8, CD14, CD19, NCAM1 (CD56), TCR αβ, and others.

• Naked Antibodies: Support custom labeling (e.g., biotin, fluorescent dyes).

Technical Advantages:

• Exceptional sensitivity and specificity for complex samples like PBMCs.

Detail

TAGEx CAR-Analytical Tools

Companion Detection Tools:

• CAR-Specific Antibodies: Targeting scFv (e.g., FMC63), VHH, G4S nanobodies, hinge/transmembrane domains, and intracellular signaling motifs.

• Quality Control: Simulated sample testing and reduced background signals (outperforms Company C).

Lentiviral Vector Services:

• Target Proteins: CD19 (leukemia), BCMA (multiple myeloma), Her2 (breast cancer), GPC3 (hepatocellular carcinoma), etc.

• Key Features: High transduction efficiency, low genotoxicity, and support for multi-gene payloads (≤6.5 kb).

Service Workflow:

• Lentivirus packaging → CAR-T cell engineering → Functional validation → Preclinical/clinical trial support

Detail